What is VolitionRx?
VolitionRx is a multinational epigenetic company dedicated to improving health outcomes through earlier detection and monitoring of life-altering diseases. The company focuses on developing and commercializing simple, cost-effective blood tests for diagnosing and monitoring various conditions, including certain cancers and sepsis, by analyzing epigenetic markers. This approach aims to provide crucial diagnostic information at an earlier stage, potentially saving lives and improving patient care for both humans and animals.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $11.3M across 4 funding rounds:
Private Equity
$1.5M
Debt
$5.5M
Stock/Share Issuance
$2M
Other Financing Round
$2.3M
Private Equity (2022): $1.5M with participation from Namur Invest Capital Risk
Debt (2023): $5.5M, investors not publicly disclosed
Stock/Share Issuance (2026): $2M supported by The Lind Partners
Other Financing Round (2026): $2.3M featuring Namur Invest and Wallonie Entreprendre
Key Investors in VolitionRx
The Lind Partners
The Lind Partners is an institutional fund manager specializing in providing growth capital to publicly traded small- and mid-cap companies across various regions. They focus on direct investments and syndicated equity offerings, having completed over 100 direct investments totaling more than US$1 billion since 2011.
Namur Invest
Namur Invest is a financial partner for businesses in the Namur province, offering tailored financing solutions including equity funds and loans to support company creation, innovation, and growth. They invest in projects with development potential and aim to strengthen the financial structure of businesses.
Wallonie Entreprendre
Wallonie Entreprendre is a company operating within the restaurant industry, focused on supporting businesses in Wallonia. They provide various financing services to help companies thrive and achieve their objectives, contributing to the economic development of the region.
What's next for VolitionRx?
The substantial enterprise-level funding indicates VolitionRx is poised for significant scaling and further development of its diagnostic technologies. This capital infusion is expected to accelerate the commercialization of its blood tests, expand its research and development capabilities, and potentially broaden its market reach. The strategic nature of the recent investment suggests a focus on enhancing operational capacity and solidifying its position in the competitive diagnostics landscape. VolitionRx's trajectory points towards a phase of aggressive growth and market penetration, leveraging its epigenetic expertise to address unmet needs in disease diagnosis and monitoring.
See full VolitionRx company page
